NRx is a clinical-stage, small molecule pharmaceutical company which develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. NRx is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the "NRx Antidepressant Drug Regimen"). NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.
Incorporated Address
NRx Pharmaceuticals, Inc.
1201 Orange Street
Suite 600
Wilmington, DE 19801
T: 484-254-6134